Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 19/20 | 0.66 |
| ▸ | ABCC8 | Q09428 | 19/20 | 0.66 |
| ▸ | KCNJ11 | Q14654 | 19/20 | 0.66 |
| ▸ | KCNJ8 | Q15842 | 19/20 | 0.66 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431549 | 0.93 | ABCC9 (0.58) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL6433306 | 0.85 | ABCC9 (0.66) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL7242134 | 0.84 | ABCC9 (0.73) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL7241131 | 0.84 | ABCC9 (0.73) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL7235400 | 0.81 | ABCC9 (0.69) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6432209 | 0.81 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6435701 | 0.79 | ABCC9 (0.58) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL6437342 | 0.79 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6437306 | 0.78 | ABCC9 (0.68) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6470293 | 0.77 | GPR174 (0.60) | ABCC9ABCC8KCNJ11KCNJ8GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194429-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2005-03-30 | — | — | EP | claimed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | claimed |
| EP-1194429-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |